Cannabidiol (CBD) Infusion into Healthcare Products Industry Growing Faster Than Expected - Seite 3
Tilray Inc. (NASDAQ:TLRY), a global leader in cannabis research, production and distribution, announced this week that Tilray 2:100, a product produced at Tilray's federally licensed, Good Manufacturing Practice (GMP)-certified facility in Canada, was successfully imported into the United Kingdom, to supply a pediatric patient in need. The changing regulatory measures in the United Kingdom (UK) previously prohibited the use of medical cannabis. However, in July 2018, Home Secretary Sajid Javid announced that clinicians will now legally be able to prescribe cannabis-derived medicines to patients with an exceptional clinical need noting "recent cases involving sick children made it clear to me that our position on cannabis-related medicinal products was not satisfactory."
Lesen Sie auch
GW Pharmaceuticals plc (NASDAQ:GWPH) is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product
platform in a broad range of disease areas. The Company, along with its U.S. subsidiary Greenwich Biosciences, announced last month that the U.S. Food and Drug Administration (FDA) has approved
EPIDIOLEX® (cannabidiol) oral solution for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome in patients two years of age or older. EPIDIOLEX is the first
prescription pharmaceutical formulation of highly-purified, plant-derived cannabidiol (CBD), a cannabinoid lacking the high associated with marijuana, and the first in a new category of
anti-epileptic drugs (AEDs). Product availability is pending rescheduling which is expected to occur within 90 days. LGS and Dravet syndrome, which develop in childhood, are rare, severe forms of
epilepsy that are notoriously treatment-resistant. Most patients with LGS and Dravet syndrome require multiple seizure medications and the majority are resistant to currently approved AEDs.
DISCLAIMER: MarketNewsUpdates.com (MNU) is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. MNU is
NOT affiliated in any manner with any company mentioned herein. MNU and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser,
holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. MNU's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy,
sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to
perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished
content and details which were previously disseminated by the companies mentioned in this release. MNU is not liable for any investment decisions by its readers or subscribers. Investors are
cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed MNU has been compensated twenty five hundred
dollars for news coverage of the current press releases issued by Cannabis Strategic Ventures, Inc by a non-affiliated third party. MNU HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.